Selective increase in plasma tumor necrosis factor-α and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis

被引:101
作者
Bekker, LG
Maartens, G
Steyn, L
Kaplan, G
机构
[1] Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA
[2] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa
[3] Univ Cape Town, Dept Med Microbiol, ZA-7925 Cape Town, South Africa
关键词
D O I
10.1086/517479
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The initiation of antituberculosis treatment in patients with severe tuberculosis may be accompanied by clinical deterioration and even death before any improvement occurs. To investigate this phenomenon newly diagnosed human immunodeficiency virus-negative adults with severe tuberculosis were followed for the first 42 days of standard short-course therapy. Clinical status, serum lactate, plasma cytokine, and plasma cytokine receptor levels were monitored on days 0, 3, and 7 and then weekly for up to 42 days. Following 7 days of antituberculosis therapy, a significant transient decrease in mean Karnofsky score (P < .001), a concomitant increase in serum lactate (P = .06), a decrease in patient weight (P = .02), and an increase in plasma tumor necrosis factor-alpha (TNF-alpha) concentrations (P =.04) were observed. Plasma levels of soluble interleukin-2 receptor, interferon-gamma, interleukin-6, and TNF-alpha receptor decreased over the 42-day study period. These observations suggest that increases in plasma TNF-alpha levels may be associated with clinical deterioration observed early in the treatment of severe tuberculosis.
引用
收藏
页码:580 / 584
页数:5
相关论文
共 15 条
[1]  
[Anonymous], 1890, DTSCH MED WOCHENSCHR, DOI DOI 10.1055/S-0029-1207546
[2]   Induction of monocyte expression of tumor necrosis factor alpha by the 30-kD alpha antigen of Mycobacterium tuberculosis and synergism with fibronectin [J].
Aung, H ;
Toossi, Z ;
Wisnieski, JJ ;
Wallis, RS ;
Culp, LA ;
Phillips, NB ;
Phillips, M ;
Averill, LE ;
Daniel, TM ;
Ellner, JJ .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (05) :1261-1268
[3]  
BERMUDEZ LEM, 1988, J IMMUNOL, V140, P3006
[4]  
BEUTLER B, 1987, NEW ENGL J MED, V316, P379
[5]   DIFFERENCES IN THERAPEUTIC EFFICACY AMONG CELL WALL-ACTIVE ANTIBIOTICS IN A MOUSE MODEL OF GRAM-NEGATIVE SEPSIS [J].
BUCKLIN, SE ;
MORRISON, DC .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (06) :1519-1527
[6]  
JOHNSON BJ, 1995, CYTOKINES MOL THER, V1, P185
[7]  
Karnofsky DA., 1949, CLIN EVALUATION CHEM, P196
[8]   THE INDUCING ROLE OF TUMOR NECROSIS FACTOR IN THE DEVELOPMENT OF BACTERICIDAL GRANULOMAS DURING BCG INFECTION [J].
KINDLER, V ;
SAPPINO, AP ;
GRAU, GE ;
PIGUET, PF ;
VASSALLI, P .
CELL, 1989, 56 (05) :731-740
[9]  
LEES AJ, 1980, LANCET, V1, P1208
[10]   SERUM CYTOKINES IN JUVENILE RHEUMATOID-ARTHRITIS - CORRELATION WITH CONVENTIONAL INFLAMMATION PARAMETERS AND CLINICAL SUBTYPES [J].
MANGGE, H ;
KENZIAN, H ;
GALLISTL, S ;
NEUWIRTH, G ;
LIEBMANN, P ;
KAULFERSCH, W ;
BEAUFORT, F ;
MUNTEAN, W ;
SCHAUENSTEIN, K .
ARTHRITIS AND RHEUMATISM, 1995, 38 (02) :211-220